All In Biotech

Drug Trial Radar · NCT07668466

Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

A Phase I/II, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 4, 2026

Primary completion

Aug 31, 2028

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Cartago Biotech Pty LtdIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out if a new medicine can help people who have long-lasting back pain caused by damaged spinal discs. The study will also check if the medicine is safe to use. The main questions this study aims to answer are: Is the medicine safe, and what amount works best? Can it reduce long-term back pain? Researchers will test a medicine called CBT005, which contains a healing protein, by injecting it into the spinal discs. They will watch closely to see how people respond to the treatment. Participants will: Receive one study injection into the spinal disc Visit the clinic in person during the first 12 months for checkups Receive phone calls at 24 and 36 months to see how they are doing Still be able to get other pain treatments in the future, including surgery, if needed

Conditions

  • Disc Degenerative Disease
  • Back Pain

Interventions

  • High DoseBiological

    High Dose: 4 mg dose of Growth differentiation factor 6

  • Low DoseBiological

    Low dose: 2mg dose of Growth differentiation factor 6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neurological StatusTime frame: From enrollment through to 12 months
  2. Oswestry Disability Index (ODI)Time frame: Enrollment through to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spine & Scoliosis Service

    Kogarah, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.